Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Rossari Biotech Equity-to-Asset Related Terms
Rossari Biotech Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Rossari Biotech's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ROSSARI vs LIN, SHW, ECL: Equity-to-Asset Comparison
For the Specialty Chemicals subindustry, Rossari Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rossari Biotech Equity-to-Asset vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Rossari Biotech's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Rossari Biotech's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Rossari Biotech's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rossari Biotech (NSE:ROSSARI) has a Equity-to-Asset of 0.00 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Rossari Biotech and its competitors. Over the past decade, Rossari Biotech's Equity-to-Asset has ranged from 0.50 to 0.75. According to the industry distribution chart, Rossari Biotech ranks #838 out of 1624 companies in the Chemicals industry, placing it in the top 51.6%.
Is Rossari Biotech's Equity-to-Asset too high?
Rossari Biotech's current Equity-to-Asset is 0.00. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 0.75. Based on the distribution chart, Rossari Biotech ranks #838 out of 1624 companies in the Chemicals industry, which is below the industry midpoint. Overall, Rossari Biotech has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rossari Biotech's Equity-to-Asset compare to LIN and SHW?
According to the Chemicals industry distribution chart, Rossari Biotech ranks #838 out of 1624 companies for Equity-to-Asset. This places Rossari Biotech in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Historically, Rossari Biotech's own Equity-to-Asset has ranged from 0.50 to 0.75 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Chemicals company?
The median Equity-to-Asset among Chemicals companies is 0.60, based on 1,624 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Rossari Biotech and its competitors. For the Chemicals industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rossari Biotech's current Equity-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rossari Biotech stock overvalued right now?
Based on GuruFocus' analysis, Rossari Biotech (NSE:ROSSARI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹927.10, compared to a current price of ₹446.15 — trading 51.9% below its estimated fair value. The current Equity-to-Asset is 0.00. Rossari Biotech's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Rossari Biotech (NSE:ROSSARI), the current Equity-to-Asset is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rossari Biotech (NSE:ROSSARI) Overvalued in 2026?
Based on GuruFocus' analysis, Rossari Biotech stock appears to be undervalued.
The current stock price of ₹446.15 is trading 51.9% below its estimated GF Value™ of ₹927.10.
GuruFocus considers Rossari Biotech to be Possible Value Trap.
Key valuation signals for NSE:ROSSARI:
Equity-to-Asset: 0.00
GF Value™: ₹927.10 vs. price of ₹446.15 (51.9% below fair value)
No single metric tells the full story. See the NSE:ROSSARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rossari Biotech Ltd is a specialty chemical manufacturing company. It provides customized solutions to specific industrial and production requirements of its customers in the FMCG, apparel, poultry, and animal feed industries through its product portfolio comprising home, personal care, and performance chemicals; textile specialty chemicals; and animal health and nutrition products. Its business is organized into three categories: home, personal care, and performance chemicals; textile specialty chemicals; and animal health and nutrition products. Its products include soaps and detergents, paints, inks and coatings, ceramics and tiles, water treatment chemicals, pulp and paper, and cleaning chemical formulations, among others. The company generates the majority revenue from India.
85GF Score
Get the complete analysis for NSE:ROSSARI
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ROSSARI has been successfully added to your 
